Add Tribune As Your Trusted Source
TrendingVideosIndia
Opinions | CommentEditorialsThe MiddleLetters to the EditorReflections
UPSC | Exam ScheduleExam Mentor
State | Himachal PradeshPunjabJammu & KashmirHaryanaChhattisgarhMadhya PradeshRajasthanUttarakhandUttar Pradesh
City | ChandigarhAmritsarJalandharLudhianaDelhiPatialaBathindaShaharnama
World | ChinaUnited StatesPakistan
Diaspora
Features | The Tribune ScienceTime CapsuleSpectrumIn-DepthTravelFood
Business | My Money
News Columns | Straight DriveCanada CallingLondon LetterKashmir AngleJammu JournalInside the CapitalHimachal CallingHill ViewBenchmark
Don't Miss
Advertisement

PGI chosen for validation of rapid antigen testing

The test approved for Covid diagnosis gives results in 30 minutes

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Yearly Premium ₹999 ₹349/Year
Yearly Premium $49 $24.99/Year
Advertisement

Tribune News Service

Advertisement

Chandigarh, June 28

Advertisement

The Post Graduate Institute of Medical Education and Research (PGIMER) is among the seven sites chosen by the Indian Council of Medical Research (ICMR) for validation of the rapid point-of-care antigen detection tests for Covid-19.

As per the initial plan, both rapid antigen and RT-PCR tests will be conducted on around 300 patients. The results will then be collated for authenticity and other parameters.

The PGI Director, Prof Jagat Ram, said, “The availability of an antigen-based detection test is very limited across the world. Most of such tests have relatively moderate sensitivity, but high specificity. The test is a promising tool to keep a track of Covid patients by rapid testing. We are thankful to the ICMR for having entrusted us with this responsibility and we will strengthen our capacities wherever required.”

Advertisement

Further detailing about the execution plan, he said, “A committee will be constituted to work out the modalities and comprehensive plan, along with timelines, to meet the desired expectations of the ICMR and contribute towards containing the pandemic.”

Need for antigen for mass testing

A letter from the ICMR dated June 25 read, “The gold standard RT-PCR diagnostic test for Covid-19 has limitations in terms of widespread availability. In view of this, there is an urgent requirement of reliable and convenient rapid point of care antigen detection assays with high sensitivity and specificity. Such assays could be used as potential diagnostic tests in all possible public and private healthcare settings and made available for mass testing,” the letter further reads.”

How it’s different from rt-pcr test

Advertisement
Show comments
Advertisement